Aspen Neuroscience reports positive 12‑month ASPIRO results
Aspen Neuroscience has unveiled promising 12-month safety, tolerability, and efficacy results from its Phase 1/2a ASPIRO trial at the AD/PD 2026 conference, focusing on Sasineprocel (ANPD001) for Parkinson’s disease. This first-in-human study involved eight patients aged 50–70, with both low and high dosing cohorts demonstrating numerical improvements in key clinical measures, including significant enhancements in “Good ON” time and reductions in MDS-UPDRS scores.
These findings are crucial for the longevity and healthspan field as they highlight the potential of cell-based therapies in managing Parkinson’s disease, a condition that significantly impacts quality of life. The positive outcomes, coupled with the lack of serious adverse events, suggest a favorable safety profile and therapeutic promise, paving the way for further clinical exploration.
As Aspen prepares to advance to a Phase 3 study later this year, the implications for future Parkinson’s treatments are substantial. I encourage you to read the full article for a deeper dive into these findings and their potential impact on the field.